156 related articles for article (PubMed ID: 17576061)
1. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.
Gilmore JL; King BW; Asakawa N; Harrison K; Tebben A; Sheppeck JE; Liu RQ; Covington M; Duan JJ
Bioorg Med Chem Lett; 2007 Aug; 17(16):4678-82. PubMed ID: 17576061
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
[TBL] [Abstract][Full Text] [Related]
3. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Yang A; Chen XT; Xue CB; Roderick J; Liu RQ; Covington MB; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1413-7. PubMed ID: 17188863
[TBL] [Abstract][Full Text] [Related]
5. Discovery and SAR of hydantoin TACE inhibitors.
Yu W; Guo Z; Orth P; Madison V; Chen L; Dai C; Feltz RJ; Girijavallabhan VM; Kim SH; Kozlowski JA; Lavey BJ; Li D; Lundell D; Niu X; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Sun J; Tong L; Umland S; Wong MK; Yang DY; Zhou G
Bioorg Med Chem Lett; 2010 Mar; 20(6):1877-80. PubMed ID: 20172725
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.
Gilmore JL; King BW; Harris C; Maduskuie T; Mercer SE; Liu RQ; Covington MB; Qian M; Ribadeneria MD; Vaddi K; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2006 May; 16(10):2699-704. PubMed ID: 16516466
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
Guo Z; Orth P; Wong SC; Lavey BJ; Shih NY; Niu X; Lundell DJ; Madison V; Kozlowski JA
Bioorg Med Chem Lett; 2009 Jan; 19(1):54-7. PubMed ID: 19054672
[TBL] [Abstract][Full Text] [Related]
10. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
[TBL] [Abstract][Full Text] [Related]
11. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
13. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
14. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
15. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Chen L; Lu Z; Jiang B; Asakawa N; Sheppeck JE; Liu RQ; Covington MB; Pitts W; Kim SH; Decicco CP
Bioorg Med Chem Lett; 2007 Jan; 17(1):266-71. PubMed ID: 17027261
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
[TBL] [Abstract][Full Text] [Related]
17. 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.
Dai C; Li D; Popovici-Muller J; Zhao L; Girijavallabhan VM; Rosner KE; Lavey BJ; Rizvi R; Shankar BB; Wong MK; Guo Z; Orth P; Strickland CO; Sun J; Niu X; Chen S; Kozlowski JA; Lundell DJ; Piwinski JJ; Shih NY; Siddiqui MA
Bioorg Med Chem Lett; 2011 May; 21(10):3172-6. PubMed ID: 21458257
[TBL] [Abstract][Full Text] [Related]
18. Reverse hydroxamate-based selective TACE inhibitors.
Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
[TBL] [Abstract][Full Text] [Related]
19. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
[TBL] [Abstract][Full Text] [Related]
20. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.
Yang JS; Chun K; Park JE; Cho M; Seo J; Song D; Yoon H; Park CH; Joe BY; Choi JH; Kim MH; Han G
Bioorg Med Chem; 2010 Dec; 18(24):8618-29. PubMed ID: 21078557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
